Samrat Pharmachem Limited is an India-based manufacturer of iodine salts. The Company is engaged in the business of pharmaceutical chemicals. Its products include 3-5 Di Iodosalicylic Acid, Ammonium Iodide, Cadmium Iodide, Calcium Iodate, Clioquinol, Copper Iodide, Ethyl Iodide, Ethylenediamine Dihydroiodide, Hydroiodic Acid 57%, Iodine, Iodine Monochloride, Iodine Monochloride, Iodoquinol, Methyl Iodide, N-Iodo Succinimide, Periodic Acid, Potassium Iodate, Potassium Iodide, Potassium Metaper Iodate, Povidone Iodine, Selenium Dioxide, Sodium Iodate, Sodium Iodide, Sodium Metaper Iodate. These products are offered for the agrochemical, animal feed, chemical, cosmetics, food, pharmaceutical, painting and textile industries. The Company exports its products to geographics such as the United States, Europe, Africa, Asia, the Middle East and others.
SAMRAT PHARMACHEM LTD. Financial Highlights
- Revenue: SAMRAT PHARMACHEM LTD. reported revenue of ₹290.55 crore in FY26 vs ₹286.83 crore in FY25. It showed an increase of 1.30% on a yearly basis.
- Operating Profit: SAMRAT PHARMACHEM LTD. reported an operating loss of ₹2.98 crore in FY26 vs ₹9.89 crore in FY25. It showed a decrease of 130.13% on a year-on-year basis.
- Net Profit: SAMRAT PHARMACHEM LTD. reported a net loss of ₹3.31 crore in FY26 vs ₹7.11 crore in FY25. It showed a decrease of 146.55% on a yearly basis.
SAMRAT PHARMACHEM LTD. Quarterly Result Highlights
- SAMRAT PHARMACHEM LTD. reported revenue of ₹71.46 crore in Mar 2026, compared with ₹63.83 crore in Dec 2025, representing an increase of 11.95% on a quarter-on-quarter (QoQ) basis.
- SAMRAT PHARMACHEM LTD. reported an operating loss of ₹1.87 crore in Mar 2026, compared with ₹0.57 crore in Dec 2025, representing a decrease of 228.07% on a quarter-on-quarter (QoQ) basis.
- SAMRAT PHARMACHEM LTD. reported a loss of ₹2.04 crore in Mar 2026, compared with ₹0.46 crore in Dec 2025, reflecting a decrease of 343.48% on a QoQ basis.
- The earnings per share (EPS) of SAMRAT PHARMACHEM LTD. stood at ₹23.02 during Mar 2026.